BeyondSpring (NASDAQ:BYSI) Stock Price Down 7.3% - Should You Sell?

Key Points

• BeyondSpring Inc. shares dropped by 7.3%, trading at $1.66 after reaching an intraday low of $1.65, marking a notable increase in trading volume of 178% compared to the average session.
• The company's recent earnings report indicated a loss of ($0.04) earnings per share (EPS) for the last quarter, reflecting ongoing challenges.
• An institutional investor, Geode Capital Management LLC, significantly increased its stake in BeyondSpring by 951.4%, acquiring an additional 231,844 shares, now holding approximately 0.64% of the company's stock.

BeyondSpring Inc. (NASDAQ:BYSI - Get Free Report) shares fell 7.3% during mid-day trading on Tuesday . The stock traded as low as $1.65 and last traded at $1.66. 87,077 shares traded hands during trading, an increase of 178% from the average session volume of 31,378 shares. The stock had previously closed at $1.79.

BeyondSpring Stock Down 7.3%

The firm's 50-day moving average price is $1.91 and its 200-day moving average price is $1.87.

BeyondSpring (NASDAQ:BYSI - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC lifted its position in shares of BeyondSpring Inc. (NASDAQ:BYSI - Free Report) by 951.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,212 shares of the company's stock after purchasing an additional 231,844 shares during the period. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 40.29% of the company's stock.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.